Yiming (Beijing) Cell Biotechnology Co., Ltd, also known as Ubrigene, a gene and cell therapy contract development and manufacturing organization (CDMO) founded in Beijing in 2015, has reportedly raised “hundreds of millions” of renminbi in a Series C financing round. The round was led by Goldstone Investment and CLSA Capital, with contributions from BGI Co-win, Huagai Capital, IDG Capital, and others. This follows previous funding rounds, including RMB 200 million ($28 million) in Series B financing in September 2021 and RMB 120 million ($16.7 million) in Series A financing in December 2020.
Use of Proceeds
The proceeds from the Series C financing will be used to accelerate the company’s global layout, including the construction of CMC research and development centers in the US and Canada. The funding will also support advancements in CGT carrier technology, process development and innovation, and the expansion of CDMO services.
Company Overview and Future Outlook
Ubrigene is a leading CDMO in the gene and cell therapy space, providing comprehensive solutions for the development and manufacturing of innovative therapies. With the support of this latest financing round, Ubrigene is well-positioned to enhance its global presence and drive innovation in the field of gene and cell therapy, ultimately contributing to the development of next-generation treatments for various diseases.-Fineline Info & Tech
